Uniqure Stock Pops After FDA Says It Can Resume Gene Therapy Tests

The Food and Drug Administration said Monday that Uniqure can resume testing its hemophilia B gene therapy, and QURE stock popped. The hold followed a patient’s liver cancer diagnosis.
Read More